PT-141 (Bremelanotide): What the Research Actually Shows

What is PT-141 (bremelanotide)?

PT-141 — generic name bremelanotide — is a synthetic cyclic peptide of seven amino acids that switches on melanocortin receptors in the brain. Unlike most compounds sold in peptide forums, it has a genuine regulatory milestone behind it: in June 2019 the US Food and Drug Administration approved it as Vyleesi to treat hypoactive sexual desire disorder (HSDD) in premenopausal women (PubMed 31893927).

Its origin story is unusual. PT-141 is a metabolite of Melanotan II, a melanocortin peptide first developed at the University of Arizona as a "sunless tanning" agent — a superpotent stimulator of skin pigmentation (PubMed 8637402). During early human testing of that tanning peptide, researchers noticed an unexpected effect: spontaneous erections. That observation redirected an entire drug program. Palatin Technologies refined the molecule into PT-141, keeping the sexual activity while trimming the skin-darkening potency, and characterized it as a melanocortin agonist for sexual dysfunction (PubMed 12851303). If you want the tanning side of that family tree, our page on Melanotan II and the pigmentation peptides covers it.

So there are really two PT-141s in circulation. One is Vyleesi: a specific 1.75 mg subcutaneous product, made to pharmaceutical standards, with a prescribing label and years of trial data. The other is a powder or vial sold online as a "research chemical," reconstituted and injected without any of that oversight. They share a molecule and almost nothing else.

How PT-141 works: the melanocortin pathway

PT-141 is fundamentally different from the erectile-dysfunction drugs most people know. Viagra and Cialis are PDE5 inhibitors: they act on blood vessels, boosting the nitric-oxide signal that relaxes smooth muscle so blood can fill erectile tissue. They handle the plumbing. They do nothing for desire.

Bremelanotide works upstream, in the brain. It activates melanocortin receptors — principally the type-4 receptor (MC4R), with some activity at MC3R — that sit in hypothalamic circuits governing sexual arousal and motivation. Animal work established this route years before the human trials: melanocortin receptor agonists trigger penile erection and increase sexual motivation through central pathways rather than direct vascular action (PubMed 11035391). That central mechanism is exactly why the drug ended up being developed for desire in women rather than mechanical erection in men — desire is a brain problem, and PDE5 inhibitors never addressed it.

The same melanocortin system explains the drug's quirks. MC1R sits on pigment cells, which is why frequent dosing can darken skin. Melanocortin signaling also touches nausea and cardiovascular tone, which is why those show up as the most common side effects rather than as rare surprises.

The RECONNECT trials: what bremelanotide actually did

The approval rested on two identical phase 3 studies, together known as RECONNECT (Studies 301 and 302). Each was randomized, double-blind, and placebo-controlled, enrolling premenopausal women diagnosed with HSDD who took bremelanotide 1.75 mg by subcutaneous injection on an as-needed basis over 24 weeks (PubMed 31599840).

The two co-primary endpoints were changes in a validated desire score (the Female Sexual Function Index desire domain) and in desire-related distress (an item from the Female Sexual Distress Scale). On both, bremelanotide beat placebo with statistical significance. The increase in desire score was 0.30 in Study 301 and 0.42 in Study 302 (0.35 in the integrated analysis, all P<.001), with parallel, significant reductions in distress.

Two independent phase 3 wins are a real result, and the effect held up on longer follow-up. An open-label extension carried responders out to 52 weeks and reported that the improvements in desire and distress were maintained, with a consistent safety picture (PubMed 31599847). A separate responder analysis from the earlier phase 2b dose-ranging program showed the same directional signal that justified moving to phase 3 (PubMed 31277966), and the original dose-finding trial had first established the 1.75 mg dose as the workable balance of benefit and tolerability (PubMed 27181790).

Does PT-141 actually work?

Yes — and the honest version of "yes" is smaller than the marketing version. The published effect sizes for as-needed bremelanotide fall in the range of roughly 0.49 to 0.61 for improving desire and 0.60 to 0.62 for reducing distress. Those are small-to-moderate effects. They are meaningful for a subset of women and unremarkable for others.

The single most important honesty check is a secondary endpoint the marketing rarely mentions: the number of satisfying sexual events did not increase significantly over placebo in the RECONNECT trials (PubMed 31599840). In other words, women reported wanting sex more and feeling less distressed about their low desire, but the drug did not clearly increase how often satisfying sex actually happened. HSDD is defined by desire and distress, so the trial hit its targets — but that nuance matters, and any source claiming PT-141 transforms sex lives is overselling the data.

A RECONNECT exit study asked participants directly about their experience and found that women who continued treatment generally valued it, which is consistent with a drug that helps a responder subgroup rather than everyone who tries it (PubMed 33538638). The reasonable summary: bremelanotide is a modestly effective, evidence-backed option for a specific diagnosis, not a general-purpose libido switch.

PT-141 side effects reported in trials

This is where the trade-off lives, and the numbers are specific. In the phase 3 program, the standout adverse effect was nausea, reported by roughly 40% of women on bremelanotide versus a low single-digit rate on placebo. About 13% used an anti-nausea medication, most nausea was mild to moderate, and it tended to be worst after the first dose (PubMed 31599840).

Beyond nausea, flushing and headache each occurred in more than 10% of participants, and injection-site reactions were common. Discontinuation tells the real tolerability story: roughly 18% of women in the bremelanotide arms stopped treatment because of adverse events, compared with a low rate on placebo — a meaningful drop-out driven mostly by nausea. This is a drug a fair number of people try and abandon.

One melanocortin-specific effect deserves its own line. Because the compound touches pigment pathways, focal hyperpigmentation — darkening of the face, gums, or breasts — was seen in about 1% of women, more often with frequent dosing than with occasional use, and it did not always fully resolve after stopping. That is the same pigmentary mechanism that makes its cousin Melanotan II darken skin, surfacing here as a side effect rather than the goal.

Does PT-141 raise blood pressure?

Yes, transiently, and this cardiovascular signal is the reason the drug's use is fenced off. Melanocortin activation raises blood pressure and slows heart rate, and researchers characterized the pattern carefully using 24-hour ambulatory blood-pressure monitoring (PubMed 27977473).

In practice, each dose produces a small increase in systolic and diastolic pressure that peaks a few hours after injection and resolves within about 12 hours, accompanied by a modest fall in heart rate. For a healthy person taking it occasionally, that transient bump is minor. The concern is stacking it against existing risk. The Vyleesi label advises against use in people with uncontrolled hypertension or known cardiovascular disease, and it caps how often the drug can be taken — no more than one dose in 24 hours and no more than eight per month — specifically to limit cumulative blood-pressure exposure.

A phase 1 study also examined bremelanotide taken together with alcohol in healthy volunteers, part of the standard safety workup for an on-demand sexual-health drug that people will predictably use around drinking (PubMed 28189361). The grey-market problem is obvious here: none of these guardrails — the dosing cap, the cardiovascular screening, the purity control — exist for a vial bought online.

PT-141 for men: off-label use and the missing approval

PT-141 is heavily marketed to men, and the male story is older than the female one — but it never crossed the approval line. Palatin originally developed PT-141 as an intranasal treatment for erectile dysfunction. Early studies were genuinely encouraging: a double-blind evaluation in healthy men and men with mild-to-moderate ED found dose-dependent erectile responses to intranasal PT-141 (PubMed 14963471). A follow-up showed that combining low-dose intranasal PT-141 with sildenafil produced a greater erectile response than sildenafil alone (PubMed 15833522), and a later randomized trial tested it as a "salvage" option in men who had failed sildenafil (PubMed 18206919).

Then the program stalled. The blood-pressure increases seen with the intranasal formulation raised regulatory concerns, and the erectile-dysfunction development was discontinued. Bremelanotide was reformulated as a lower-dose subcutaneous product and repositioned toward female HSDD, which is the indication that ultimately won approval. The male ED evidence therefore froze in the phase 2 era: small, older, and never confirmed by the kind of large phase 3 trials that support approved men's-health drugs.

What that means today: a physician can legally prescribe the approved women's product off-label for a man, because off-label prescribing is lawful and routine — but "off-label" here means resting on decade-plus-old, small studies, not on a modern approval for men. And the vials sold directly to men as a research chemical carry no approval at all. Some carry the same warnings we cover for other unregulated melanocortin analogues, where uncontrolled use has produced real harms (PubMed 28266027).

PT-141 vs Viagra and flibanserin (Addyi)

The comparison people actually search for is between three very different drugs. Viagra fixes mechanics. Flibanserin (Addyi) and bremelanotide (Vyleesi) are the two FDA-approved drugs for low desire in premenopausal women — and even they work in opposite ways: a daily pill versus an on-demand injection.

The key takeaways: Viagra and PT-141 are not competitors — one restores an erection, the other targets desire, which is why early research tested them together in men. And between the two approved desire drugs, bremelanotide's on-demand dosing appeals to women who dislike a daily pill, at the cost of an injection and frequent nausea. None of the three is a testosterone product, and none is a peptide sold for tissue repair like BPC-157 or immune modulation like thymosin alpha-1 — a reminder that "peptide" covers wildly different molecules and evidence levels.

Is PT-141 legal and FDA approved?

Both questions have a two-part answer, and conflating the parts is where buyers get misled.

As Vyleesi, PT-141 is FDA-approved and fully legal: a prescription drug dispensed by a pharmacy, made to pharmaceutical manufacturing standards, with a label, a defined indication, and a monitored safety profile. That is the version the entire clinical evidence base is about.

As a research chemical, PT-141 is neither approved nor legal to sell for human use. Vials marketed online "for research purposes only" are not manufactured to drug-quality standards; their purity, sterility, and even their actual contents are unverified. Selling them for people to inject is unlawful in most jurisdictions, and buying them means taking a molecule with a real cardiovascular signal without any of the screening that the approved product requires. Our overview of peptide legality and regulatory status walks through why "FDA-approved as a drug" and "sold as a research chemical" are opposite ends of the spectrum, even for the exact same molecule. PT-141 is one of the clearest examples of that split — most peptides marketed for injection, from GHK-Cu to the repair compounds, sit entirely on the unapproved side.

How long does PT-141 take to work?

Two different timelines are worth separating. Per the approved label, Vyleesi is injected subcutaneously at least 45 minutes before anticipated sexual activity — so a single on-demand dose is timed in the tens of minutes, not taken continuously like flibanserin. That is the acute window.

The trial timeline is different. RECONNECT measured its desire and distress endpoints over 24 weeks of as-needed use, not from one injection, and the open-label extension tracked responders to 52 weeks (PubMed 31599847). The benefit on desire is something that shows up as a pattern across repeated use in the people it helps, not a guaranteed switch that flips the first time. That is also exactly the kind of subjective, weeks-long effect where memory is unreliable and a written record beats a hunch — the same reasoning behind our guide to tracking peptides and medications consistently.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. PT-141: a melanocortin agonist for the treatment of sexual dysfunction — PubMed 12851303
2. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide — PubMed 8637402
3. Melanocortin receptor agonists, penile erection, and sexual motivation — PubMed 11035391
4. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction — PubMed 14963471
5. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response — PubMed 15833522
6. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study — PubMed 18206919
7. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial — PubMed 27181790
8. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide — PubMed 31277966
9. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials — PubMed 31599840
10. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder — PubMed 31599847
11. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results — PubMed 33538638
12. New Drug Approved for Treating Hypoactive Sexual Desire Disorder — PubMed 31893927
13. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide — PubMed 27977473
14. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants — PubMed 28189361
15. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues — PubMed 28266027

Keep reading